Pineal region glioblastomas display features of diffuse midline and non-midline gliomas

被引:12
|
作者
D'Amico, Randy S. [1 ]
Zanazzi, George [2 ]
Wu, Peter [1 ]
Canoll, Peter [2 ]
Bruce, Jeffrey N. [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Neurol Surg, New York, NY 10027 USA
[2] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA
关键词
Pineal tumor; Pineal gland; Pineal glioma; Glioblastoma; Brain tumor; Histone H3 K27M; 3RD VENTRICULOSTOMY; PARENCHYMAL TUMORS; ENDOSCOPIC BIOPSY; MULTIFORME; MANAGEMENT; RESECTION; CLASSIFICATION; DISSEMINATION; TEMOZOLOMIDE; EXPERIENCE;
D O I
10.1007/s11060-018-2931-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pineal region glioblastomas (GBM) are very rare, with approximately 46 cases described in the literature. The epidemiology, pathogenesis, and treatment of these lesions are poorly characterized. We identified all cases of pineal region GBM treated surgically at our institution between 1990 and 2017. Demographic and clinical follow-up data were extracted from the medical records for all cases. Pathology was reviewed and classified according to 2016 World Health Organization (WHO) criteria. Specific attention was given to the frequency of histone H3 K27M mutations in these midline gliomas. Eight patients (seven men, one woman) with pineal region GBM, WHO grade IV, were identified. The most common presenting symptoms were headache (75%), vision changes (75%), and gait imbalance/ataxia (50%). Median age at diagnosis was 48.5 years (range 36-74 years). Radical subtotal resection, via a supracerebellar infratentorial approach, was achieved in 75% of patients. Review of the surgical pathology revealed seven primary GBMs (including one giant cell GBM) and one pineal region GBM that developed three years after resection of a pineal parenchymal tumor of intermediate differentiation. No cases demonstrated evidence of IDH-1 R132H mutation (N = 6) or 1p/19q co-deletion (N = 3). One case tested positive for the histone H3 K27M-mutation. Targeted exome sequencing of 467 cancer-related genes revealed nonsense mutations in ATRX and NF1. Adjuvant radiation and chemotherapy was employed in 87.5% and 75.0% of patients, respectively. Median overall survival (OS) was 15 months (range 2-24 months) from GBM diagnosis. This study expands the clinical and pathologic spectrum of pineal region GBM, and provides the first report of the genetic landscape of these tumors.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 50 条
  • [31] GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas
    Majzner, Robbie G.
    Ramakrishna, Sneha
    Yeom, Kristen W.
    Patel, Shabnum
    Chinnasamy, Harshini
    Schultz, Liora M.
    Richards, Rebecca M.
    Jiang, Li
    Barsan, Valentin
    Mancusi, Rebecca
    Geraghty, Anna C.
    Good, Zinaida
    Mochizuki, Aaron Y.
    Gillespie, Shawn M.
    Toland, Angus Martin Shaw
    Mahdi, Jasia
    Reschke, Agnes
    Nie, Esther H.
    Chau, Isabelle J.
    Rotiroti, Maria Caterina
    Mount, Christopher W.
    Baggott, Christina
    Mavroukakis, Sharon
    Egeler, Emily
    Moon, Jennifer
    Erickson, Courtney
    Green, Sean
    Kunicki, Michael
    Fujimoto, Michelle
    Ehlinger, Zach
    Reynolds, Warren
    Kurra, Sreevidya
    Warren, Katherine E.
    Prabhu, Snehit
    Vogel, Hannes
    Rasmussen, Lindsey
    Cornell, Timothy T.
    Partap, Sonia
    Fisher, Paul G.
    Campen, Cynthia J.
    Filbin, Mariella G.
    Grant, Gerald
    Sahaf, Bita
    Davis, Kara L.
    Feldman, Steven A.
    Mackall, Crystal L.
    Monje, Michelle
    NATURE, 2022, 603 (7903) : 934 - +
  • [32] Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma
    Wagner, Matthias W.
    Namdar, Khashayar
    Napoleone, Marc
    Hainc, Nicolin
    Amirabadi, Afsaneh
    Fonseca, Adriana
    Laughlin, Suzanne
    Shroff, Manohar M.
    Bouffet, Eric
    Hawkins, Cynthia
    Khalvati, Farzad
    Bartels, Ute
    Ertl-Wagner, Birgit B.
    CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 2023, 74 (01): : 119 - 126
  • [33] Extra-neural metastases in pediatric diffuse midline gliomas, H3 K27-altered: presentation of two cases and literature review
    De Martino, Lucia
    Picariello, Stefania
    Russo, Carmela
    Errico, Maria Elena
    Spennato, Pietro
    Papa, Maria Rosaria
    Normanno, Nicola
    Scimone, Giuseppe
    Colafati, Giovanna Stefania
    Cacchione, Antonella
    Mastronuzzi, Angela
    Massimino, Maura
    Cinalli, Giuseppe
    Quaglietta, Lucia
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2023, 16
  • [34] Cerebral salt wasting syndrome as a probable cause of postoperative polyuria in patients with supratentorial Non-midline tumors: A prospective observational study with targeted and quantitative metabolomic approach
    Shi, Lei
    Wang, Yu-Fang
    Zhang, Guo-Feng
    Li, Yan
    Yao, Ming-Li
    Li, Jing-Chao
    Qiu, Chun-Fang
    Yao, Shun
    Ouyang, Bin
    Wang, Ling-Yan
    NEUROSURGICAL REVIEW, 2025, 48 (01)
  • [35] H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients
    Vuong, Huy Gia
    Le, Hieu Trong
    Ngo, Tam N. M.
    Fung, Kar-Ming
    Battiste, James D.
    McNall-Knapp, Rene
    Dunn, Ian F.
    JOURNAL OF NEURO-ONCOLOGY, 2021, 155 (03) : 225 - 234
  • [36] MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
    Abe, Hideaki
    Natsumeda, Manabu
    Kanemaru, Yu
    Watanabe, Jun
    Tsukamoto, Yoshihiro
    Okada, Masayasu
    Yoshimura, Junichi
    Oishi, Makoto
    Fujii, Yukihiko
    NEUROLOGIA MEDICO-CHIRURGICA, 2018, 58 (07) : 290 - 295
  • [37] Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
    Mount, Christopher W.
    Majzner, Robbie G.
    Sundaresh, Shree
    Arnold, Evan P.
    Kadapakkam, Meena
    Haile, Samuel
    Labanieh, Louai
    Hulleman, Esther
    Woo, Pamelyn J.
    Rietberg, Skyler P.
    Vogel, Hannes
    Monje, Michelle
    Mackall, Crystal L.
    NATURE MEDICINE, 2018, 24 (05) : 572 - +
  • [38] Leptomeningeal dissemination in H3 K27M-mutant diffuse midline gliomas: clinical characteristics, risk factors, and prognostic insights
    Zhong, Shuai
    Zuo, Jinyi
    Fu, Xiaojun
    Wu, Chenxing
    Liu, Rui
    Huang, Zheng
    Li, Shouwei
    JOURNAL OF NEURO-ONCOLOGY, 2025, : 437 - 445
  • [39] Deep learning-based prediction of H3K27M alteration in diffuse midline gliomas based on whole-brain MRI
    Huang, Bowen
    Zhang, Yuekang
    Mao, Qing
    Ju, Yan
    Liu, Yanhui
    Su, Zhengzheng
    Lei, Yinjie
    Ren, Yanming
    CANCER MEDICINE, 2023, 12 (16): : 17139 - 17148
  • [40] Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
    Pearson, Andrew D. J.
    Mueller, Sabine
    Filbin, Mariella G.
    Grill, Jacques
    Hawkins, Cynthia
    Jones, Chris
    Donoghue, Martha
    Drezner, Nicole
    Weiner, Susan
    Russo, Mark
    Dun, Matthew D.
    Allen, Joshua E.
    Alonso, Marta
    Benaim, Ely
    Buenger, Vickie
    de Rojas, Teresa
    Desserich, Keith
    Fox, Elizabeth
    Friend, John
    Bender, Julia Glade
    Hargrave, Darren
    Jensen, Michael
    Kholmanskikh, Olga
    Kieran, Mark W.
    Knoderer, Holly
    Koschmann, Carl
    Lesa, Giovanni
    Ligas, Franca
    Lipsman, Nir
    Ludwinski, Donna
    Marshall, Lynley
    McDonough, Joe
    McNicholl, Adrian G.
    Mirsky, David
    Monje, Michelle
    Nysom, Karsten
    Pappo, Alberto
    Rosenfield, Amy
    Scobie, Nicole
    Slaughter, Joan
    Smith, Malcolm
    Souweidane, Mark
    Straathof, Karin
    Ward, Lisa
    Weigel, Brenda
    Zamoryakhin, Dmitry
    Karres, Dominik
    Vassal, Gilles
    EUROPEAN JOURNAL OF CANCER, 2025, 217